Ferenc Renyi-Vamos
Overview
Explore the profile of Ferenc Renyi-Vamos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
942
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Csaba M, Ghimessy A, Radeczky P, Megyesfalvi Z, Kocsis A, Agocs L, et al.
Orv Hetil
. 2025 Feb;
166(6):203-209.
PMID: 39923214
No abstract available.
2.
Megyesfalvi E, Ghimessy A, Bauer J, Pipek O, Saghi K, Gellert A, et al.
Lung Cancer
. 2025 Jan;
200:108111.
PMID: 39889465
Background: Complementary prognostic markers are needed in thymic epithelial tumors (TETs) to aid patient stratification and determine the most appropriate follow-up strategies. This study aimed to assess the diagnostic and...
3.
Csaba M, Megyesfalvi Z, Bathory-Fulop L, Pinter T, Agocs L, Dome B, et al.
Front Oncol
. 2025 Jan;
14():1462865.
PMID: 39777340
Gestational trophoblastic neoplasms are tumors that occur during pregnancy, while non-gestational trophoblastic tumors have a similar histology but are present outside of gestation. Literature reports several cases of non-gestational trophoblastic...
4.
Ghimessy A, Radeczky P, Torok K, Bogyo L, Csende K, Meszaros L, et al.
Magy Onkol
. 2024 Sep;
68(3):223-228.
PMID: 39299688
Our goal was to examine the postoperative indicators after the first 300 thoracic robotic cases in the National Institute of Oncology. We retrospectively analyzed the clinicopathological and postoperative indicators of...
5.
Bogyo L, Torok K, Illes Z, Szilvasi A, Szekely B, Bohacs A, et al.
Respir Res
. 2024 Jul;
25(1):262.
PMID: 38951782
Background: Donor-specific antibodies (DSAs) are common following lung transplantation (LuTx), yet their role in graft damage is inconclusive. Mean fluorescent intensity (MFI) is the main read-out of DSA diagnostics; however...
6.
Ferencz B, Torok K, Pipek O, Fillinger J, Csende K, Lantos A, et al.
Cancer Immunol Immunother
. 2024 May;
73(6):114.
PMID: 38693435
Background: Advancements in immunotherapeutic approaches only had a modest impact on the therapy of lung neuroendocrine neoplasms (LNENs). Our multicenter study aimed to investigate the expression patterns of novel immunotherapy...
7.
Lang C, Megyesfalvi Z, Lantos A, Oberndorfer F, Hoda M, Solta A, et al.
World J Surg Oncol
. 2024 Feb;
22(1):57.
PMID: 38369463
Background: By being highly involved in the tumor evolution and disease progression of small cell lung cancer (SCLC), Myc family members (C-Myc, L-Myc, and N-Myc) might represent promising targetable molecules....
8.
Berta J, Ferencz B, Horvath L, Fillinger J, Lantos A, Bogos K, et al.
Magy Onkol
. 2023 Sep;
67(3):181-192.
PMID: 37768117
Small-cell lung cancer (SCLC) is a highly aggressive malignancy characterised by genomic instability and early metastatic spread. Patients are typically diagnosed at advanced disease stage, when platinum-based chemotherapy with immunotherapy...
9.
Megyesfalvi Z, Heeke S, Drapkin B, Solta A, Kovacs I, Boettiger K, et al.
Cancer Cell
. 2023 Sep;
41(9):1535-1540.
PMID: 37699331
The understanding of small cell lung cancer (SCLC) biology has increased dramatically in recent years, but the processes that allow SCLC to progress rapidly remain poorly understood. Here, we advocate...
10.
Megyesfalvi Z, Gay C, Popper H, Pirker R, Ostoros G, Heeke S, et al.
CA Cancer J Clin
. 2023 Jun;
73(6):620-652.
PMID: 37329269
Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity. It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority of SCLCs exhibit...